Marco C. Pinho

Marco C. Pinho

Auto-generated profile, based on publicly available information

Marco C. Pinho

University of Texas Southwestern Medical Center, Dallas, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 November 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
TBTracy T. Batchelor
Tracy T. Batchelor
EGElizabeth R. Gerstner
Elizabeth R. Gerstner
KEKyrre Emblem
Kyrre Emblem
DDDan G. Duda
Dan G. Duda
JKJayashree Kalpathy-Cramer
Jayashree Kalpathy-Cramer
RJRakesh K. Jain
Rakesh K. Jain
Significance: This study demonstrates that antiangiogenic therapy increases tumor blood perfusion in a subset of newly diagnosed glioblastoma patients, and that it is these patients who survive longer when this expensive and potentially toxic therapy is combined with standard radiation and chemotherapy. This study provides fresh insights into the selection of glioblastoma patients most likely to benefit from antiangiogenic treatments.

14 May 2015 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Open access
PDF file
LLLuis M. De León‐Rodríguez
Luis M. De León‐Rodríguez
André F. MartinsAndré F. Martins
André F. Martins
MPMarco C. Pinho
Marco C. Pinho
NRNeil M. Rofsky
Neil M. Rofsky
ASA. Dean Sherry
A. Dean Sherry
The diagnostic capabilities of magnetic resonance imaging (MRI) have undergone continuous and substantial evolution by virtue of hardware and software innovations and the development and implementation of exogenous contrast media. Thirty years since the first MRI contrast agent was approved for clinical use, a reliance on MR contrast media persists, largely to improve image quality with higher contrast resolution and to provide additional functional characterization of normal and abnormal tissues. Further development of MR contrast media is an important component in the quest for continued augmentation of diagnostic capabilities. In this review we detail the many important considerations when pursuing the design and use of MR contrast media. We offer a perspective on the importance of chemical stability, particularly kinetic stability, and how this influences one's thinking about the safety of metal–ligand‐based contrast agents. We discuss the mechanisms involved in MR relaxation in the context of probe design strategies. A brief description of currently available contrast agents is accompanied by an in‐depth discussion that highlights promising MRI contrast agents in the development of future clinical and research applications. Our intention is to give a diverse audience an improved understanding of the factors involved in developing new types of safe and highly efficient MR contrast agents and, at the same time, provide an appreciation of the insights into physiology and disease that newer types of responsive agents can provide. J. Magn. Reson. Imaging 2015;42:545–565.

1 September 2007 in RadioGraphics
Verified
Journal Article
Closed access
ACAngela Hissae Motoyama Caiado
Angela Hissae Motoyama Caiado
RBRoberto Blasbalg
Roberto Blasbalg
AMAntonio Sergio Zafred Marcelino
Antonio Sergio Zafred Marcelino
MPMarco da Cunha Pinho
Marco da Cunha Pinho
MCMaria Cristina Chammas
Maria Cristina Chammas
MMMarcel Cerqueira César Machado
Marcel Cerqueira César Machado
Liver transplantation is currently an accepted first-line treatment for patients with end-stage acute or chronic liver disease, but postoperative complications may limit the long-term success of transplantation. The most common and most clinically significant complications are arterial and venous thrombosis and stenosis, biliary disorders, fluid collections, neoplasms, and graft rejection. Early diagnosis is crucial to the successful management of all these complications, and imaging plays an important role in the diagnosis of all but graft rejection. A multimodality approach including ultrasonography and cross-sectional imaging studies often is most effective for diagnosis. Each imaging modality has specific strengths and weaknesses, and the diagnostic usefulness of a modality depends mainly on the patient's characteristics, the clinical purpose of the imaging evaluation, and the expertise of imaging professionals.

15 September 2016 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
PTP. Tiwari
P. Tiwari
PPPrateek Prasanna
Prateek Prasanna
LWL. Wolansky
L. Wolansky
MPM. Pinho
M. Pinho
MCM. Cohen
M. Cohen
Anant MadabhushiAnant Madabhushi
Anant Madabhushi
BACKGROUND AND PURPOSE: Despite availability of advanced imaging, distinguishing radiation necrosis from recurrent brain tumors noninvasively is a big challenge in neuro-oncology. Our aim was to determine the feasibility of radiomic (computer-extracted texture) features in differentiating radiation necrosis from recurrent brain tumors on routine MR imaging (gadolinium T1WI, T2WI, FLAIR). MATERIALS AND METHODS: A retrospective study of brain tumor MR imaging performed 9 months (or later) post-radiochemotherapy was performed from 2 institutions. Fifty-eight patient studies were analyzed, consisting of a training (n = 43) cohort from one institution and an independent test (n = 15) cohort from another, with surgical histologic findings confirmed by an experienced neuropathologist at the respective institutions. Brain lesions on MR imaging were manually annotated by an expert neuroradiologist. A set of radiomic features was extracted for every lesion on each MR imaging sequence: gadolinium T1WI, T2WI, and FLAIR. Feature selection was used to identify the top 5 most discriminating features for every MR imaging sequence on the training cohort. These features were then evaluated on the test cohort by a support vector machine classifier. The classification performance was compared against diagnostic reads by 2 expert neuroradiologists who had access to the same MR imaging sequences (gadolinium T1WI, T2WI, and FLAIR) as the classifier. RESULTS: On the training cohort, the area under the receiver operating characteristic curve was highest for FLAIR with 0.79; 95% CI, 0.77–0.81 for primary (n = 22); and 0.79, 95% CI, 0.75–0.83 for metastatic subgroups (n = 21). Of the 15 studies in the holdout cohort, the support vector machine classifier identified 12 of 15 studies correctly, while neuroradiologist 1 diagnosed 7 of 15 and neuroradiologist 2 diagnosed 8 of 15 studies correctly, respectively. CONCLUSIONS: Our preliminary results suggest that radiomic features may provide complementary diagnostic information on routine MR imaging sequences that may improve the distinction of radiation necrosis from recurrence for both primary and metastatic brain tumors.

1 April 2015 in Radiology
Verified
Journal Article
Closed access
KEKyrre Emblem
Kyrre Emblem
MPMarco C. Pinho
Marco C. Pinho
FZFrank G Zöllner
Frank G Zöllner
PDPaulina Due-Tonnessen
Paulina Due-Tonnessen
JHJohn K. Hald
John K. Hald
ABAtle Bjornerud
Atle Bjornerud
To develop a generic support vector machine (SVM) model by using magnetic resonance (MR) imaging-based blood volume distribution data for preoperative glioma survival associations and to prospectively evaluate the diagnostic effectiveness of this model in autonomous patient data. Institutional and regional medical ethics committees approved the study, and all patients signed a consent form. Two hundred thirty-five preoperative adult patients from two institutions with a subsequent histologically confirmed diagnosis of glioma after surgery were included retrospectively. An SVM learning technique was applied to MR imaging-based whole-tumor relative cerebral blood volume (rCBV) histograms. SVM models with the highest diagnostic accuracy for 6-month and 1-, 2-, and 3-year survival associations were trained on 101 patients from the first institution. With Cox survival analysis, the diagnostic effectiveness of the SVM models was tested on independent data from 134 patients at the second institution. were adjusted for known survival predictors, including patient age, tumor size, neurologic status, and postsurgery treatment, and were compared with survival associations from an expert reader. Compared with total qualitative assessment by an expert reader, the whole-tumor rCBV-based SVM model was the strongest parameter associated with 6-month and 1-, 2-, and 3-year survival in the independent patient data (area under the receiver operating characteristic curve, 0.794-0.851; hazard ratio, 5.4-21.2). Machine learning by means of SVM in combination with whole-tumor rCBV histogram analysis can be used to identify early patient survival in aggressive gliomas. The SVM model returned higher diagnostic accuracy values than an expert reader, and the model appears to be insensitive to patient, observer, and institutional variations.

4 March 2021 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
CYChandan Ganesh Bangalore Yogananda
Chandan Ganesh Bangalore Yogananda
BSB.R. Shah
B.R. Shah
SNS.S. Nalawade
S.S. Nalawade
GMG.K. Murugesan
G.K. Murugesan
FYF.F. Yu
F.F. Yu
JMJ.A. Maldjian
J.A. Maldjian
Motivation Whole-genome DNA sequencing (WGS) enables the discovery of non-coding variants, but tools are lacking to prioritize the subset that functionally impacts human phenotypes. DNA sequence variants that disrupt or create transcription factor binding sites (TFBS) can modulate gene expression. find-tfbs efficiently scans phased WGS in large cohorts to identify and count TFBSs in regulatory sequences. This information can then be used in association testing to find putatively functional non-coding variants associated with complex human diseases or traits. Results We applied find-tfbs to discover functional non-coding variants associated with hematological traits in the NHLBI Trans-Omics for Precision Medicine (TOPMed) WGS dataset (Nmax=44,709). We identified >2000 associations at P<1×10−9, implicating specific blood cell-types, transcription factors and causal genes. The vast majority of these associations are captured by variants identified in large genome-wide association studies (GWAS) for blood-cell traits. find-tfbs is computationally efficient and robust, allowing for the rapid identification of non-coding variants associated with multiple human phenotypes in very large sample size. Availability https://github.com/Helkafen/find-tfbs and https://github.com/Helkafen/find-tfbs-demo Contacts sebastian.meric.de.bellefon@umontreal.ca and guillaume.lettre@umontreal.ca Supplementary information Supplementary data are available.